ARPA-H EVIDENT program selects Motif Neurotech alongside other behavioral health teams — $139M initiative deploys capital
Summary
ARPA-H's EVIDENT (Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health) program deployed capital to its first selected teams in April 2026, with Motif Neurotech among the recipients. The EVIDENT program funds collection of precision biomarker data alongside behavioral health clinical trials to identify which patients are most likely to respond to specific interventions, how treatments work, and what constitutes early signals of efficacy. EVIDENT is part of the broader $139M ARPA-H behavioral health initiative.
Why it matters
ARPA-H EVIDENT selection for Motif gives their RESONATE trial a biomarker data collection mandate from a federal agency — creating a public scientific record of treatment response prediction alongside the FDA safety trial. This dual-track design is unprecedented for psychiatric device trials and could generate the biomarker evidence base that eventually enables personalized psychiatric BCI prescribing based on pretreatment EEG and neural signatures.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial